Тема: Мексидол.
Показать сообщение отдельно
Старый 26.06.2008, 13:15   #8
незарегистрированный
Гость
 
Сообщений: n/a
По умолчанию

Уважаемая коллега гадать не надо, надо верить, ссылку дать не могу, не откроется, вставлю текст.
Neuroprotection – a rational approach for acute ischemic stroke
MedWire – European Stroke Conference (Brussels, Belgium), May 17, 2006: This educational satellite symposium addressed the use of neuroprotection strategies in acute stroke, with a focus on NXY-059, a novel free-radical-trapping agent that is the first neuroprotectant agent to demonstrate efficacy in advanced clinical trials.
NXY-059 is the first neuroprotectant to meet all STAIR criteria, Dr. Davis said, and is also the only such agent to have demonstrated efficacy in phase III clinical trials. The drug is a novel free-radical-trapping agent that acts at several points in the ischemic cascade. NXY-059 reduces infarct size in both transient and permanent infarct models and has a window of opportunity of at least 4 hours. In a marmoset permanent occlusion model, treatment improved motor deficits and spatial neglect, decreased infarct size, and showed long-term histological and functional benefits.
“Extensive phase I/II clinical experience has shown that NXY-059 is well tolerated in acute ischemic and intracerebral hemorrhagic stroke,” Dr. Davis concluded. “The first phase III clinical trial, SAINT I, was positive, and SAINT II is well underway.”

Дальше если честно копировать все лень Надеюсь коллега мы не будем обвинять друг друга впредь в голословности.
  Ответить с цитированием